Pharma News

The FDA has inspected a Bavarian Nordic manufacturing facility in Denmark which manufactures a monkeypox vaccine that’s now awaiting the agency’s green light to ship to the United States. ...

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypo...

The FDA granted Fast Track status to Anthos Therapeutics’ investigational monoclonal antibody, abelacimab, for treatment of patients with cancer-associated blood clots. ...

The FDA has approved Horizon Therapeutics’ supplemental Biologics License Application (sBLA) for its injectable drug, Krystexxa (pegloticase), coadministered with methotrexate for patients with u...

Researchers successfully transplanted genetically modified pig hearts into two recently deceased people connected to ventilators, the New York University team announced today. ...

AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer’s disease candidate AL003, which aims to tackle the neurodegenerative disease by restoring reduced immune s...

Vertex Pharmaceuticals has entered into a $320 million agreement to acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies...

Israeli scientists say they have used a natural chemical to make pigs’ wounds heal twice as fast as they otherwise would.

The head of the World Health Organisaton (WHO) has urged governments across the world to deploy measures like masking and improved ventilation amid unacceptably high numbers of deaths. ...

The FDA has granted full approved to Pfizer-BioNTech’s COVID-19 vaccine for children aged 12 to 15 years old, making it the only FDA-approved vaccine for that age group. ...

Sobi has inked a licensing agreement with ADC Therapeutics for the company’s cancer drug, Zynlonta (loncastuximab tesirine-lpyl), for treatment of all hematologic and solid tumor indications out...

The FDA has declined NRx Pharmaceuticals’ Emergency Use Authorization (EUA) application a second time for Zyesami (aviptadil), this time for a subgroup of COVID-19 patients at immediate risk of ...